Aricept Complexed with Acetylcholinesterase (Slovak)
From Proteopedia
(Difference between revisions)
| (2 intermediate revisions not shown.) | |||
| Line 14: | Line 14: | ||
==O tejto štruktúre== | ==O tejto štruktúre== | ||
| - | 1EVE je štruktúra so sekvenciou z [http://en.wikipedia.org/wiki/Torpedo_californica Torpedo californica]. Jún 2004 RCSB PDB [http://pdb.rcsb.org/pdb/static.do?p=education_discussion/ | + | 1EVE je štruktúra so sekvenciou z [http://en.wikipedia.org/wiki/Torpedo_californica Torpedo californica]. Jún 2004 RCSB PDB [http://pdb.rcsb.org/pdb/static.do?p=education_discussion/Molecule_of_the_Month/index.html Molecule of the Month] na tému ''Acetylcholinesteráza'' od David S. Goodsell je [http://dx.doi.org/10.2210/rcsb_pdb/mom_2004_6 10.2210/rcsb_pdb/mom_2004_6]. Plná kryštalografická informáciaje dostupná na [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1EVE OCA]. |
==Ďalšie informácie== | ==Ďalšie informácie== | ||
| Line 23: | Line 23: | ||
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=10368299 10368299] | Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=10368299 10368299] | ||
| - | [[ar: | + | [[ar:Aricept_Complexed_with_Acetylcholinesterase (Arabic)]] |
| - | [[ca: | + | [[ca:Aricept_Complexed_with_Acetylcholinesterase (Catalan)]] |
| - | [[cs: | + | [[zh:Aricept_Complexed_with_Acetylcholinesterase (Chinese)]] |
| - | [[de: | + | [[cs:Aricept_Complexed_with_Acetylcholinesterase (Czech)]] |
| - | [[en: | + | [[de:Aricept_Complexed_with_Acetylcholinesterase (German)]] |
| - | [[es: | + | [[en:Aricept_Complexed_with_Acetylcholinesterase]] |
| - | [[fr: | + | [[es:Aricept_Complexed_with_Acetylcholinesterase (Spanish)]] |
| - | [[he: | + | [[fr:Aricept_Complexed_with_Acetylcholinesterase (French)]] |
| - | [[it: | + | [[he:Aricept_Complexed_with_Acetylcholinesterase (Hebrew)]] |
| - | [[ru: | + | [[it:Aricept_Complexed_with_Acetylcholinesterase (Italian)]] |
| - | [[sk: | + | [[ru:Aricept_Complexed_with_Acetylcholinesterase (Russian)]] |
| - | + | [[sk:Aricept_Complexed_with_Acetylcholinesterase (Slovak)]] | |
| - | [[vi: | + | [[vi:Aricept_Complexed_with_Acetylcholinesterase (Vietnamese)]] |
| - | [[ | + | [[tr:Aricept_Complexed_with_Acetylcholinesterase (Turkish)]] |
[[Category: Acetylcholinesterase]] | [[Category: Acetylcholinesterase]] | ||
Current revision
| |||||||||||
Referencie
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:10368299

